CN101069734A - Chinese medicine composition for vascular cretinism and preparing method therefor - Google Patents
Chinese medicine composition for vascular cretinism and preparing method therefor Download PDFInfo
- Publication number
- CN101069734A CN101069734A CNA2006100788439A CN200610078843A CN101069734A CN 101069734 A CN101069734 A CN 101069734A CN A2006100788439 A CNA2006100788439 A CN A2006100788439A CN 200610078843 A CN200610078843 A CN 200610078843A CN 101069734 A CN101069734 A CN 101069734A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- group
- yellow
- qing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 109
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 26
- 230000002792 vascular Effects 0.000 title description 2
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 20
- 241000208340 Araliaceae Species 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims description 118
- 229940079593 drug Drugs 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 241000237903 Hirudo Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 241000208966 Polygala Species 0.000 claims description 10
- 241001077909 Sigesbeckia Species 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 4
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- -1 s Species 0.000 abstract description 2
- 241000209495 Acorus Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 124
- 241000700159 Rattus Species 0.000 description 114
- 238000012360 testing method Methods 0.000 description 77
- 241000699670 Mus sp. Species 0.000 description 70
- 102000019197 Superoxide Dismutase Human genes 0.000 description 51
- 108010012715 Superoxide dismutase Proteins 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 47
- 210000004369 blood Anatomy 0.000 description 41
- 239000008280 blood Substances 0.000 description 41
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 230000015654 memory Effects 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 29
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 28
- 230000002490 cerebral effect Effects 0.000 description 27
- 206010008118 cerebral infarction Diseases 0.000 description 26
- 201000006474 Brain Ischemia Diseases 0.000 description 21
- 206010008120 Cerebral ischaemia Diseases 0.000 description 21
- 230000002146 bilateral effect Effects 0.000 description 21
- 210000001168 carotid artery common Anatomy 0.000 description 21
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 21
- 238000012549 training Methods 0.000 description 21
- 230000037396 body weight Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 206010012289 Dementia Diseases 0.000 description 18
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- 238000012109 statistical procedure Methods 0.000 description 18
- 229960004756 ethanol Drugs 0.000 description 16
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 15
- 230000032683 aging Effects 0.000 description 12
- 239000003172 expectorant agent Substances 0.000 description 12
- 230000003419 expectorant effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 11
- 230000009189 diving Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 229960002748 norepinephrine Drugs 0.000 description 9
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 9
- 238000010998 test method Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 210000005257 cortical tissue Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 235000010288 sodium nitrite Nutrition 0.000 description 8
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 7
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 7
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 210000004055 fourth ventricle Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 7
- 229960002646 scopolamine Drugs 0.000 description 7
- 208000002381 Brain Hypoxia Diseases 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000005611 electricity Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000037920 primary disease Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000579423 Homo sapiens Regulator of nonsense transcripts 1 Proteins 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000036831 Moderate mental retardation Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100028287 Regulator of nonsense transcripts 1 Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Abstract
The present invention relates to a Chinese medicine composition for curing vascular dementia with excellent therapeutic effect. Said Chinese medicine composition includes 11 Chinese medicinal materials of turmeric, notoginseng, acorus root, leech, poria ginseng and others through a certain preparation process.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used for the treatment of vascular dementia and preparation method thereof, belong to the Chinese herbal and crude drugs preparations technical field.Be mainly used in the treatment vascular dementia clinically, card belongs to obstruction of collaterals by blood stasis, the turbid key type that closes of expectorant.Disease is seen hypophrenia, headache, and the lip onyx is livid purple, heaviness of the head as if it were tightly bandaged, indigestion and loss of appetite abdominal distention, look quietly, dim complexion, scaly dry skin, limbs are stranded heavy, purplish tongue or the ecchymosis petechia is arranged, greasy fur, rolling pulse or heavy slow, puckery.
Background technology
(Vascular Dementiva VD) is the chronic brain syndrome that is caused by various cerebrovascular to vascular dementia.Belong to categories such as the traditional Chinese medical science " dementia ", " literary composition is silly ", " forgetful ".In China, because the pilosity of cerebrovascular makes VD become one of disease occurred frequently.Most data shows that the sickness rate of VD was 700,000 people/years, and the prevalence of Japan's report is American-European high.In China, how much reporting of VD prevalence differed the generaI investigation in comprehensive 11 cities and rural area, among the old people more than 60 years old, the prevalence of VD is 3,42/,100,000 populations, and its prevalence in city and rural area is respectively 4,78/,100,000 and 1,40/,100,000, and the prevalence in city is apparently higher than the rural area.Show according to Epidemiological study
[i], over-65s crowd VD sickness rate is about 4%～6%, then is 15%～20% more than 80 years old.Because its sickness rate, disability rate, case fatality rate are all higher, thus one of important diseases that threatens crowd's life at advanced age become, and give social and family brings heavy burden.Therefore, explore the important topic of VD early prevention and treatment measure having become modern scientific research and clinical practice.
Up to now, the core symptom to VD is that mentally disabled does not still have solution preferably.Doctor trained in Western medicine is main path to the treatment of Patients with Vascular Dementia to improve the cerebrum blood circulation, to promote cerebral metabolism, strengthen the neurotransmission function.In general, these medicines can improve dementia symptom to a certain extent to slight dementia patients or delay dull-witted progress, but it is also not obvious to produce effects.The traditional Chinese medical science has shown good prospect in the treatment of VD, its curative effect is compared with present Western medicine has certain advantage.Therefore, inquire into Chinese medicine method and medicine thereof mechanism, necessary theoretical foundation will be provided for effective control of vascular dementia the vascular dementia influence.
Chinese medicine has long history to the control of vascular dementia.The yellow Pu Qing brain capsule of Chinese medicine is just according to Chinese medical theory, by deep discussion to the vascular dementia pathogenesis, at the vascular dementia clinical manifestation, the turbid pathogenic characteristic that closes key of obstruction of collaterals by blood stasis, expectorant of vascular dementia is proposed, with promoting blood circulation to remove obstruction in the collateral, waking up the patient from unconsciousness by dissipating phlegm develops in conjunction with clinical application experience for many years for the treatment rule, and being intended to provides determined curative effect, takes safe new product of Chinese medicine for Patients with Vascular Dementia.
Summary of the invention
The object of the present invention is to provide Chinese medicine composition of a kind of treatment vascular dementia evident in efficacy and preparation method thereof.
Vascular dementia belongs to the name of disease of modern medicine, TCM Document is referred to as it " idiot ", " imbecility ", " dementia ", " refreshing slow-witted ", " dementia ", " military silly " etc., and it comprises alzheimer disease, vascular dementia and the Combination dementia of modern medicine.
Ancient Chinese medicine doctor has argumentation to the etiology and pathogenesis of primary disease more, recognizes the sick position of primary disease at brain, and think suffer from a deficiency of the kidney, stagnation of liver-QI, expectorant are turbid, blood stasis, blood deficiency are to cause dull-witted reason, but also recognize that primary disease and apoplexy have relation.In recent years, modern doctor family knows from experience and the modern study achievement in conjunction with experience separately, the further perfect etiology and pathogenesis content of primary disease.The sick position of VD is at brain, and it is all dirty to relate to Liver and kidney heart spleen, closely related with the prosperity and decline of essence in kidney especially; How just to decrease because of year is high, factor such as feelings will internal injury causes the internal organs yin and yang qi and blood disorder so that the turbid poison resistance of expectorant stasis of blood network covers key, causes brain network obturation, refreshing machine apraxia and falls ill; The primary disease characteristic of disease is a deficiency in origin and excess in superficiality, and it loses void for vital essence, and it is designated as the turbid malicious internal resistance of the expectorant stasis of blood.
In sum, obstruction of collaterals by blood stasis, expectorant are turbid closes the basic pathogenesis that key is this disease.Blood stasis hinders in the brain network, and then hypophrenia, look be quietly to hoodwink gods.The stagnation of blood stasis sering, " stagnation of QI and blood may bring about pain ", so headache as thorn, the lip onyx is livid purple.Blood stasis is not all right, and the skin QI and blood is not filled, lose in moistening foster, so the meeting color dark and gloomy, scaly dry skin.Turbid the going up of expectorant covered clear key, and clear sun is not opened up, thus heaviness of the head as if it were tightly bandaged, stagnation of turbid phlegm in middle-JIAO, disorder of QI movement, then indigestion and loss of appetite abdominal distention, gastral cavity is vexed not hungry, and expectorant is turbid to be blocked in extremity, and then limbs are stranded heavy.Purplish tongue or the ecchymosis petechia is arranged, greasy fur, rolling pulse or heavy slow, puckery.Also be due to the turbid impatency brain of the blood stasis expectorant key.So this disease should be main and auxiliary to eliminate phlegm for resuscitation with promoting blood circulation to remove obstruction in the collateral, make the blood stasis must be capable, expectorant is turbid must be changed, and reaches the purpose of the refreshment of having one's ideas straightened out.
This Chinese medicine composition, with the Rhizoma Curcumae Longae is monarch drug, and minister is adjuvant drug with Radix Notoginseng, Rhizoma Acori Graminei with Hirudo, Poria, Radix Ginseng, the Radix Paeoniae Alba, Radix Polygoni Multiflori Preparata, Herba Siegesbeckiae, Rhizoma Coptidis, with the Radix Polygalae is messenger drug, all medicines share, blood circulation promoting and blood stasis dispelling, the eliminating phlegm of having one's ideas straightened out, the refreshment Fructus Alpiniae Oxyphyllae, make the blood stasis must be capable, expectorant is turbid must be changed, and reaches the purpose of the refreshment of having one's ideas straightened out.
This prescription has clinical preferably basis, and the clinical observation of having passed through a large amount of patients has tentatively proved its curative effect and safety.Apply at present medical market the treatment vascular dementia the accurate font size medicine of Chinese medicine seldom, the yellow Pu Qing brain capsule of Chinese medicine, according to Chinese medical theory, develop in conjunction with clinical application experience for many years just, being intended to provides determined curative effect, takes safe new product of Chinese medicine for Patients with Vascular Dementia., put on market as succeeding in developing so believe this product, will make significant contribution for the health of Patients with Vascular Dementia.
Medicine of the present invention is to be made by the crude drug of following weight portion ratio:
Rhizoma Curcumae Longae 300-450 part Rhizoma Acori Graminei 250-350 part Radix Notoginseng 100-150 Fen Herba Siegesbeckiae 200-300 part
Radix Ginseng 150-220 part Radix Polygoni Multiflori Preparata 150-220 part Hirudo 100-150 part Rhizoma Coptidis 150-220 part
Radix Paeoniae Alba 200-300 part Poria 150-220 part Radix Polygalae 250-350 part
The weight portion ratio of above-mentioned raw materials medicine is preferred:
250 parts of 312.5 portions of Radix Notoginseng of 375 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
187.5 parts of 125 portions of Rhizoma Coptidis of 187.5 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
312.5 parts of 187.5 parts of Radix Polygalaes of 250 parts of Poria of the Radix Paeoniae Alba
Or:
300 parts of 250 portions of Radix Notoginseng of 300 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
220 parts of 100 portions of Rhizoma Coptidis of 215 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
350 parts of 180 parts of Radix Polygalaes of 200 parts of Poria of the Radix Paeoniae Alba
Or:
300 parts of 350 portions of Radix Notoginseng of 450 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 100 Fen Herba Siegesbeckiaes
180 parts of 150 portions of Rhizoma Coptidis of 150 portions of Hirudos of 150 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
250 parts of 155 parts of Radix Polygalaes of 300 parts of Poria of the Radix Paeoniae Alba
Medicine of the present invention can be made the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, pill, oral liquid etc. by preparation process routinely.
Medicine of the present invention can be made by following preparation method:
1), the side's of getting Chinese crude drug, choosing is clean respectively, coarse crushing becomes the 5-10mm granule, presses the recipe quantity weighing.
2), get Rhizoma Curcumae Longae, add 8-12 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, 2-3 hour for the first time, 1-2 hour for the second time, extracting solution filtered, and merged, and behind the decompression recycling ethanol, suitably was condensed into relative density and was about 1.0-1.2 (60 ℃ of heat are surveyed), and is standby.
3), get Radix Notoginseng, Herba Siegesbeckiae, Radix Polygoni Multiflori Preparata, Rhizoma Coptidis, add 8-10 and doubly measure 50-70% ethanol, heating and refluxing extraction 1-3 time, each 2-3 hour, extracting liquid filtering merged, decompression recycling ethanol is condensed into relative density and is about 1.0-1.2 (60 ℃ of heat are surveyed), and is standby.
4), get Rhizoma Acori Graminei, add 8-12 times of water gaging, soak after 30-60 minute, extracted volatile oil 4-8 hour, volatile oil device is in addition collected, aqueous extract filters, and is standby.
5), water intaking trematodiasis, the Radix Paeoniae Alba, Poria, Radix Polygalae, add 8-10 times of water gaging, decoct 2-3 time, each 1-2 hour, extracting liquid filtering merged, add the aqueous solution after Rhizoma Acori Graminei is carried oil, being condensed into relative density is 1.10-1.15 (60 ℃ of heat are surveyed) clear paste, merges with extracting solution such as Rhizoma Curcumae Longae, Radix Notoginseng, mixing, put into vacuum drying oven, at temperature 60-70 ℃, drying under reduced pressure under the vacuum 0.04-0.06Mpa condition, dried cream powder is broken into 100 order powder, and is standby.
6), get Radix Ginseng, be ground into 100 order powder, standby.
7), get 5) and 6) preparation powder, add appropriate amount of auxiliary materials, formulation method is made capsule routinely.
Perhaps
With 5), 6) preparation fine powder, formulation method is made tablet, pill routinely;
Or
With 2), 3), 4), 5) in the extract of preparation, add 6) in the granule fine powder of gained, make oral liquid according to a conventional method.
The specific embodiment
Example below in conjunction with the preparation of medicine capsule of the present invention, tablet, pill and oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
250 parts of 312.5 portions of Radix Notoginseng of 375 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
187.5 parts of 125 portions of Rhizoma Coptidis of 187.5 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
312.5 parts of 187.5 parts of Radix Polygalaes of 250 parts of Poria of the Radix Paeoniae Alba
Preparation method:
1), the side's of getting Chinese crude drug, choosing is clean respectively, coarse crushing becomes the 5-10mm granule, presses the recipe quantity weighing.
2), get Rhizoma Curcumae Longae, add 10 times of amount 80% ethanol, heating and refluxing extraction 2 times, 2 hours for the first time, 1.5 hours for the second time, extracting solution filtered, and merged, and behind the decompression recycling ethanol, suitably was condensed into relative density and was about 1.0 (60 ℃ of heat are surveyed), and is standby.
3), get Radix Notoginseng, Herba Siegesbeckiae, Radix Polygoni Multiflori Preparata, Rhizoma Coptidis, add 8 times of amount 60% ethanol, heating and refluxing extraction 2 times, each 2 hours, extracting liquid filtering merged, decompression recycling ethanol is condensed into relative density and is about 1.0 (60 ℃ of heat are surveyed), and is standby.
4), get Rhizoma Acori Graminei, add 12 times of water gagings, soak after 45 minutes, extracted volatile oil 5 hours, volatile oil device is in addition collected, oil yield must not be less than 0.4%, aqueous extract filters, and is standby.
5), water intaking trematodiasis, the Radix Paeoniae Alba, Poria, Radix Polygalae, add 8 times of water gagings, decoct 2 times, each 1.5 hours, extracting liquid filtering merged, add the aqueous solution after Rhizoma Acori Graminei is carried oil, being condensed into relative density is 1.10-1.15 (60 ℃ of heat are surveyed) clear paste, merges with extracting solution such as Rhizoma Curcumae Longae, Radix Notoginseng, mixing, put into vacuum drying oven, at temperature 60-70 ℃, drying under reduced pressure under the vacuum 0.04-0.06Mpa condition, dried cream powder is broken into 100 order powder, and is standby.
6), get Radix Ginseng, be ground into 100 order powder, standby.
7), get 5) and 6) preparation powder, add appropriate amount of auxiliary materials, formulation method is made capsule routinely.
Embodiment 2:
300 parts of 250 portions of Radix Notoginseng of 300 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
220 parts of 100 portions of Rhizoma Coptidis of 215 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
350 parts of 180 parts of Radix Polygalaes of 200 parts of Poria of the Radix Paeoniae Alba
Preparation method: with among the embodiment 1 1), 2), 3), 4), 5), 6) step and make tablet according to a conventional method.
Embodiment 3:
300 parts of 350 portions of Radix Notoginseng of 450 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 100 Fen Herba Siegesbeckiaes
180 parts of 150 portions of Rhizoma Coptidis of 150 portions of Hirudos of 150 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
250 parts of 155 parts of Radix Polygalaes of 300 parts of Poria of the Radix Paeoniae Alba
Preparation method: with among the embodiment 1 1), 2), 3), 4), 5), 6) step and make pill according to a conventional method.
Embodiment 4:
200 parts of 350 portions of Radix Notoginseng of 300 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
150 parts of 125 portions of Rhizoma Coptidis of 220 portions of Hirudos of 220 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
300 parts of 220 parts of Radix Polygalaes of 250 parts of Poria of the Radix Paeoniae Alba
Preparation method: with among the embodiment 1 1), 2), 3), 4), 5) step, add 6) in the granule fine powder of gained, make oral liquid according to a conventional method.
Its capsule of pharmacological action medicine of the present invention (commodity are called yellow Pu Qing brain capsule) has carried out following animal experiment to prove its curative effect:
Yellow Pu Qing brain capsule Pharmacodynamic test of active extract
Summary: yellow Pu Qing brain capsule is 6 class new Chinese medicines of Tianshi Pharmacey Technology Development Co., Ltd., Hebei's exploitation, function: promoting blood circulation to remove obstruction in the collateral, eliminate phlegm for resuscitation.Be used for the treatment of vascular dementia, card belongs to obstruction of collaterals by blood stasis, the turbid key type that closes of expectorant.Disease is seen hypophrenia, headache, and the lip onyx is livid purple, heaviness of the head as if it were tightly bandaged, indigestion and loss of appetite abdominal distention, look quietly, dim complexion, scaly dry skin, limbs are stranded heavy.Imitate for proving this medication, we have carried out pharmacodynamics test, Pharmacodynamic test of active extract result shows: yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) can obviously improve the permanent ligation of bilateral common carotid arteries and cause the vascular dementia rats learning capacity, improve SOD vigor in serum and the cerebral tissue, reduce MDA content, increase NE, DA content in the cerebral cortex; The rising of the blood stasis rat whole blood contrast viscosity that epinephrine is caused with frozen water has the reduction effect; Can obviously improve the nervous symptoms of focal cerebral ischemia rat, dwindle infarction size, alleviate brain tissue impairment due to the local cerebral ischemia.Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) can obviously improve cerebral ischemia re-pouring and cause the mouse memory obstacle, improves SOD in serum and the cerebral tissue, total NOS vigor, reduces MDA content, suppresses the TChE vigor; Improve the learning capacity that the D-galactose causes mouse aging, improve SOD vigor in serum and the cerebral tissue, reduce MDA content; Can obviously improve scopolamine and cause the mouse memory acquired disturbance; Obviously improving sodium nitrite causes mouse memory and consolidates obstacle; Obviously improve the memory represents obstacle that ethanol causes; Dehisce the time after can prolonging the mice broken end, the chmice acute cerebral anoxia is had the certain protection effect.Result of study provides necessary pharmacology's foundation for clinical application.
One, permanent ligation causes the influence of vascular dementia rats to bilateral common carotid arteries
Test objective: permanent ligation causes the influence of vascular dementia rats to bilateral common carotid arteries by observing yellow Pu Qing brain capsule, estimates its therapeutical effect.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Hydergine (Hydergine sheet), Tianjin Hua Jin pharmaceutical factory, Novartis Pharma AG's co-production, lot number 020632.
Animal: SD rat (secondary), body weight 180--200g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Reagent: superoxide dismutase (SOD) testing cassete, malonaldehyde (MDA survey) examination box are Nanjing and build up bio-engineering research institute product; Norepinephrine (NE), dopamine (DA), 5-hydroxy tryptamine (5-TH) standard substance provide by the calibrating of Chinese biological medicine goods.
Instrument: DTT-2 keeps away camera bellows, and Chinese Academy of Medical Sciences's medicine grinds made; The 970MC spectrofluorophotometer, Shanghai analytical tool head factory.
Test method:
With reference to the permanent ligation hyperamization of bilateral common carotid arteries such as Zhao Xianlin pipe dementia rat model
[1]Water is can't help in the fasting in preceding 12 hours of rat art.Chloral hydrate 350mg/kg intraperitoneal injection of anesthesia with 10% guarantees that intra-operative has autonomous respiration.It is fixing to lie on the back, and throat portion unhairing sterilization tailing edge neck medisection is isolated bilateral common carotid arteries, the ligation of bilateral silk thread, and rat anus temperature remains on 36.5 ℃～37.5 ℃ in the art.Not ligation common carotid artery is cut in the only capable throat of 10 rats of sham operated rats.75 of rats are divided 5 groups at random in player's art success back, every group 15, be respectively model control group, yellow Pu Qing brain capsule small dose group (0.28g/kg, amount to crude drug 1.71g/kg, be equivalent to 3.5 times of the clinical consumption of people), dosage group (0.56g/kg in the yellow Pu Qing brain capsule, amount to crude drug 3.42g/kg, be equivalent to 7 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.12g/kg, amount to crude drug 6.83g/kg, be equivalent to 14 times of the clinical consumption of people) and positive drug hydergine group (1.2mg/kg is equivalent to 14 times of the clinical consumption of people).Administration group rat gastric infusion every day 1 time, capacity is the 1ml/100g body weight, sham operated rats and model control group rat are waited the capacity distilled water, continuous 60 days.Each is organized rat and kept away dark test in back 30 days, 45 days, 60 days respectively at operation, tests its learning capacity.Earlier rat head is put into bright chamber back to the hole during test, rat enters the darkroom and is subjected to electric shock and is wrong reaction, and rat enters incubation period and the errors number in the darkroom in the record 5min.After test in the 60th day finishes, the rat broken end is got blood, separation of serum, 3000rpm, 4 ℃ of centrifugal 10min get serum by specification method and detect MDA, SOD content; Each treated animal broken end is fast got brain, separates brain cortical tissue on ice pan immediately, and liquid nitrogen freezing is put in-80 ℃ of refrigerators standby.Quantitatively take by weighing brain cortical tissue and make 1% homogenate, get supernatant by specification method and detect cerebral tissue MDA, SOD equal size, the histone assay is undertaken by the Lowry method.Get brain cortical tissue and add cold acidify n-butyl alcohol 5ml homogenate, vortex oscillation, the centrifugal 5min of 3000r/min.Get supernatant 2.0ml, add normal heptane 4.0ml, 0.1mol/L HCL5.0ml, vortex oscillation, the centrifugal 5min of 3000r/min.Its water is surveyed NE, DA, 5-TH.
Statistical procedures: data are used
Spss11.0 for window statistical software is adopted in expression, statistical procedures.
Result of the test:
1. permanent ligation causes the influence of the general situation of vascular dementia rats to bilateral common carotid arteries:
In whole test in the phase, 10 rats of sham operated rats, the activity and the mental status are good, and hair color is smooth; The model control group rat has more the blepharoptosis of losing face, the movable minimizing, and the mental status is relatively poor, and dead 4 of postoperative 24 hours, has 7 death by in the process of the test dead 3; The general situation of all the other each administration group rats all has clear improvement than the model control group rat, and postoperative respectively had 5 death in 24 hours, all none death in the process of the test.
2. permanent ligation causes the influence of vascular dementia rats learning capacity to bilateral common carotid arteries:
The results are shown in Table 1, table 2, from the result as seen, 30 days after surgery, 45 days, 60 days different time points of model control group rat are significantly shorter than sham operated rats (P＜0.01) incubation period, and the 5min errors number illustrates that apparently higher than sham operated rats (P＜0.01) the preceding cerebral hyoperfusion of rat persistency has caused learning memory disorder.30 days after surgery, 45 days, 60 days different time points learning and memories of yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) group rat obviously are longer than model control group (P＜0.01) incubation period, and the 5min errors number is less than model control group (P＜0.01), shows that decline has the improvement effect to chronic brain hypoperfusion learning and memory in rats for it.
The influence (darkness avoidance test) of table 1 pair vascular dementia rat learning capacity
| Group | Dosage (g/kg) | Number of animals (only) | Wrong number (inferior) in 5 minutes | ||
| 30 days | 45 days | 60 days | |||
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | -- -- 0.28 0.56 1.12 1.2mg | 10 8 10 10 10 10 | 1.3±0.82 ** 10.4±2.56 6.3±3.12 ** 4.9±2.23 ** 5.2±1.75 ** 4.3±2.63 ** | 1.1±0.99 ** 11.2±2.31 8.3±3.02 * 3.9±2.77 ** 4.8±1.32 ** 4.1±2.60 ** | 1.0±0.94 ** 10.6±2.00 7.6±3.13 * 4.5±2.92 ** 4.5±1.43 ** 4.2±1.75 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
The influence (darkness avoidance test) of table 2 pair vascular dementia rat learning capacity
| Group | Dosage (g/kg) | Number of animals (only) | Incubation period (s) | ||
| 30 days | 45 days | 60 days | |||
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | -- -- 0.28 0.56 1.12 1.2mg | 10 8 10 10 10 10 | 193.9±30.26 ** 68.1±23.74 127.5±25.47 ** 122.8±30.41 ** 132.5±39.82 ** 119.2±14.63 ** | 188.7±29.97 **76.2±28.26 115.2±14.62 **114.7±20.83 **128.7±22.74 **127.4±21.82 ** | 189.3±22.57 **72.6±26.12 124.5±29.68 **121.7±26.05 **134.7±35.85 **124.9±28.16 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
3. to the influence of the permanent ligation hyperamization of bilateral common carotid arteries pipe dementia rat blood serum SOD, MDA
The results are shown in Table 3, from the result as seen, model control group rat blood serum MDA content obviously raises (P＜0.01) than sham operated rats, and the SOD vigor obviously obviously reduces (P＜0.01) than sham operated rats; Yellow Pu Qing brain capsule (0.56g/kg) group rat MDA content is lower than model control group, and the SOD vigor is all apparently higher than model control group (P＜0.01) in yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) the group rat blood serum.
The influence of the permanent ligation hyperamization of table 3 bilateral common carotid arteries pipe dementia SOD in serum, MDA
| Group | Dosage (g/kg) | Number of animals (only) | SOD (NU/ml) | MDA (nmol/ml) |
| The yellow Pu Qing brain capsule of sham operated rats model control group | -- -- 0.28 0.56 1.12 | 10 8 10 10 10 | 254.3±60.72 ** 131.1±38.58 235.3±54.47 ** 238.4±64.50 ** 235.8±53.87 ** | 5.49±1.47 ** 10.83±2.49 8.90±1.65 8.41±2.05 * 9.18±1.53 |
| The hydergine group | 1.2mg | 10 | 229.0±48.04 ** | 7.65±1.34 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
4. to the influence of the permanent ligation hyperamization of the bilateral common carotid arteries pipe dementia SOD of rat cerebral tissue, MDA
The results are shown in Table 4, from the result as seen, the SOD of model control group rat cerebral tissue vigor obviously reduces (P＜0.01) than sham operated rats; MDA content obviously increases (P＜0.01) than sham operated rats; Yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) the group SOD of rat cerebral tissue vigor all obviously improves (P＜0.05 or P＜0.01) than model control group, and MDA content all reduces (P＜0.05 or P＜0.01) than model control group.
The influence of the permanent ligation hyperamization of the table 4 pair bilateral common carotid arteries pipe dementia SOD of rat cerebral tissue, MDA
| Group | Dosage (g/kg | Number of animals (only) | SOD (NU/mgprot) | MDA (nmol/mgprot) |
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | -- -- 0.28 0.56 1.12 1.2mg | 10 8 10 10 10 10 | 18.8 7±2.74 ** 10.96±4.02 15.69±4.20 * 16.65±4.28 ** 15.48±3.21 ** 14.33±3.07 * | 3.88±0.71 **6.61±1.29 4.21±0.93 **4.39±1.28 **4.15±1.54 **4.61±0.80 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
5. yellow Pu Qing brain capsule is to the influence of neurotransmitter in the permanent ligation hyperamization of the bilateral common carotid arteries pipe dementia rat cerebral cortex
The results are shown in Table 5, from the result as seen, NE, DA compare obvious reduction (P＜0.01) in the model control group rat cerebral cortex tissue with sham operated rats; NE, DA content in yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) the group rat cerebral tissue all obviously increase (P＜0.05 or P＜0.01) than model control group, though and 5-TH has the trend of increasing, not statistically significant (P＞0.05).
The influence of the permanent ligation rat brain of table 5 pair bilateral common carotid arteries neurotransmitter
| Group | Dosage (g/kg) | Number of animals (only) | NE (ng/g weight in wet base | 5-HT (ng/g weight in wet base) | DA (ng/g weight in wet base) |
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | -- -- 0.28 0.56 1.12 1.2mg | 10 8 10 10 10 10 | 272.3±64.64 ** 152.9±44.66 226.9±96.92 243.4±80.27 ** 231.7±68.6 ** 254.9±72.00 ** | 443.6±92.53 ** 255.0±92.27 272.6±89.88 313.3±111.64 298.2±96.68 321.1±109.55 | 505.2±110.53 **216.8±54.16 378.6±100.69 **393.3±101.5 **427.0±91.51 **422.0±74.17 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01; Each treated animal number is the same.
Conclusion: this result of the test shows: the yellow Pu Qing brain capsule ability of learning and memory obstacle that permanent ligation causes vascular dementia rats to bilateral common carotid arteries has some improvement, can improve serum and cerebral tissue SOD vigor, reduce MDA content, increase the content of NE, DA in the brain cortical tissue.
Two, cerebral ischemia reperfusion injury is caused the influence of fourth ventricle in mice with vascular dementia
Test objective:, estimate its therapeutical effect by observing of the influence of yellow Pu Qing brain capsule to the cerebral ischemia reperfusion injury fourth ventricle in mice with vascular dementia.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Hydergine (Hydergine sheet), Tianjin Hua Jin pharmaceutical factory, Novartis Pharma AG's co-production, lot number 020632.
Animal: Kunming mouse (secondary), body weight 25--28g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Reagent: superoxide dismutase (SOD) testing cassete, malonaldehyde (MDA) testing cassete, nitricoxide synthase testing cassete, acetylcholine esterase (TChE) testing cassete are Nanjing and build up bio-engineering research institute product.
The program control water maze of instrument: SMG-2, Chinese Academy of Medical Sciences's medicine grinds made; TDL-5-A type centrifuge, Anting Scientific Instrument Factory, Shanghai; FA2004 type electronic balance, balance equipment factory of last Nereid section; 722 type grating spectrophotometers, Shanghai the 3rd analytical tool factory.
Test method
Cause the method for mice vascular dementia model with reference to making cerebral ischemia re-pourings such as Xu Qiuping
[2]Select healthy male mice, carry out Morris water maze test training before the art earlier, water maze contains 4 cecums, and terminal point has a place of safety that exceeds the water surface.Training divides to be carried out in 3 days, and condition is controlled at room temperature (22 ± 2) ℃, water temperature (25 ± 1) ℃.Earlier mice is placed 10 seconds on the step during training, make its existence of understanding this place of safety, be placed on then near the step, allow its cat ladder 2 times voluntarily, to be familiar with means of escape.The 1st day training A point, the 2nd day training B point, the 3rd day training C point, each training time all is limited to 3min, and overtime person swims over to step by 3min with Glass rod guiding animal.Reject the poor excessively mice of motility, take the mice that to swim the labyrinth as an elective course and be used for test.12h can't help water with the mice fasting before the art.With 10% chloral hydrate (350mg/kg) intraperitoneal injection of anesthesia, lying on the back is fixed on the operating-table routine disinfection, the cervical region median incision, isolate bilateral common carotid arteries (CCA), before folder closes bilateral CCA, from the about 1cm of the mouse tail point about 0.3ml of blood-letting (be circulation volume 30%) that docks, close bilateral CCA with noinvasive bulldog clamp folder immediately, behind the 20min, logical again 10min, folder closes 20min again, logical again back sew up wound is put back to insulation raising in the cage.Cut in the only capable throat of sham operated rats animal, does not block CCA, not blood-letting.Mice anus temperature remains on 36.5 ℃～37.5 ℃ in the art.50 of the mices of player's art success are divided into 5 groups at random, 10 every group.Be respectively model control group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.78g/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug hydergine group (1.5mg/kg is equivalent to 18 times of the clinical consumption of people).Administration group gastric infusion every day, capacity is the 0.2ml/10g body weight, sham operated rats and model control group mice are waited the capacity distilled water every day, once a day, back 7 days, the 14 days beginning Morris water mazes of performing the operation are tested time (time of advent) that record is reached home and the number of times (errors number) that enters cecum.After test finished, broken end was got blood, separation of serum, and 3000rpm, 4 ℃ of centrifugal 10min, get serum by specification method and detect MDA, SOD equal size: each treated animal broken end is fast got brain, separates brain cortical tissue on ice pan immediately, puts in-80 ℃ of refrigerators standby.Quantitatively take by weighing brain cortical tissue and make 1% homogenate, get supernatant by specification method detection cerebral tissue MDA content and SOD, NOS, TChE vigor, the histone assay is undertaken by the Lowry method.
Statistical procedures: data are used
Spss11.0 for window statistical software is adopted in expression, statistical procedures.
Result of the test
1. to the amnemonic influence of cerebral ischemia re-pouring dementia mice
The results are shown in Table 6, table 7, from the result as seen, the model control group mice obviously prolongs (P＜0.01) than sham operated rats the 7th day after surgery, the 14th day time of advent, the errors number that enters cecum obviously increases (P＜0.01).Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice obviously shortens (P＜0.01) than the model control group mice the 7th day after surgery, the 14th day time of advent, and the errors number that enters cecum obviously reduces (P＜0.01).
The influence (Morris water maze test) of table 6 pair fourth ventricle in mice with vascular dementia memory ability
| Group | Dosage (g/kg) | Number of animals (only) | The time of advent | |
| 7 days | 14 days | |||
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | - - 0.36 0.72 1.44 1.5mg | 10 9 10 10 10 10 | 76.1±53.01 ** 156.0±31.63 100.4±60.70 * 106.2±54.44 * 99.4±39.25 ** 102.3±63.16 * | 68.4±37.87 ** 147.6±34.00 99.4±35.00 ** 86.2±25.90 ** 95.4±42.59 ** 97.9±47.80 ** |
Compare with model control group:
*P＜0.05;
*P＜0.01
The influence (Morris water maze test) of table 7 pair fourth ventricle in mice with vascular dementia memory ability
| Group | Dosage (g/kg) | Number of animals (only) | Errors number | |
| 7 days | 14 days | |||
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | - - 0.36 0.72 1.44 1.5mg | 10 9 10 10 10 10 | 3.9±2.28 ** 8.7±3.00 4.4±2.59 ** 5.1±2.68 * 4.8±3.08 5.2±2.57 * | 2.2±1.48 ** 6.8±3.70 3.0±3.02 * 2.9±3.38 * 2.4±2.67 ** 2.5±3.10 * |
Compare with model control group:
*P＜0.05;
*P＜0.01
2. to the influence of cerebral ischemia re-pouring dementia mice SOD in serum, MDA
The results are shown in Table 8, from the result as seen, model control group mice MDA content obviously all raises (P＜0.01) than sham operated rats, and serum activity of SOD obviously obviously reduces (P＜0.01) than sham operated rats; Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice MDA content all is starkly lower than model control group (P＜0.01), and serum activity of SOD all obviously improves (P＜0.05) than model control group.
The influence of table 8 pair fourth ventricle in mice with vascular dementia SOD in serum, MDA
| Group | Dosage (g/kg) | Number of animals (only) | SOD (NU/ml) | MDA (nmol/ml) |
| The yellow Pu Qing brain capsule of sham operated rats model control group | - - 0.36 | 10 9 10 | 361.1±69.39 ** 217.2±79.01 312.7±81.74 * | 4.66±0.95 ** 9.51±2.01 5.96±1.85 ** |
| The hydergine group | 0.72 1.44 1.5mg | 10 10 10 | 294.6±105.6 333.0±98.57 * 309.3±69.77 * | 5.46±1.17 **5.65±1.06 **4.90±1.34 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01
3. to the influence of cerebral ischemia re-pouring dementia mice cerebral tissue SOD, MDA
The results are shown in Table 9, from the result as seen, model control group mouse brain tissue SOD vigor obviously reduces (P＜0.01) than sham operated rats; MDA content obviously increases (P＜0.05) than sham operated rats; Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mouse brain tissue SOD vigor all improves (P＜0.01) than the model control group mice, and MDA content all reduces (P＜0.01) than model control group.
The influence of table 9 couple fourth ventricle in mice with vascular dementia cerebral tissue SOD, MDA
| Group | Dosage (g/kg) | Number of animals (only) | SOD (NU/mgprot) | MDA (nmol/mgprot) |
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | - - 0.36 0.72 1.44 1.5mg | 10 9 10 10 10 10 | 20.45±7.10 **8.31±5.42 14.67±3.77 **15.30±7.09 **14.83±4.99 **14.11±2.70 ** | 4.78±1.06 *8.63±2.38 5.38±1.47 **5.84±1.32 **5.43±1.24 **5.96±1.19 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01
4. to the influence of cerebral ischemia re-pouring dementia mice cerebral tissue NOS, TChE vigor
The results are shown in Table 10, from the result as seen, the model control group mouse brain organizes the NOS vigor obviously to reduce (P＜0.01) than sham operated rats, and the TChE vigor is than sham operated rats obviously raise (P＜0.01); Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mouse brain organizes the NOS vigor to improve (P＜0.01) than model control group, and the TChE vigor reduces (P＜0.05 or P＜0.01) than model control group.
The influence of table 10 couple fourth ventricle in mice with vascular dementia cerebral tissue NOS, TChE
| Group | Dosage (g/kg) | Number of animals (only) | NOS (U/mgprot) | TChE (U/mgprot) |
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | - - 0.36 0.72 1.44 1.5mg | 10 9 10 10 10 10 | 6.44±1.41 **3.34±0.96 5.68±1.74 **6.46±2.40 **5.29±1.59 **5.14±1.87 ** | 0.18±0.044 **0.66±0.23 0.30±0.054 **0.46±0.050 *0.36±0.054 **0.26±0.048 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule has some improvement to the ability of learning and memory obstacle of cerebral ischemia re-pouring dementia mice, can improve serum and cerebral tissue SOD vigor, improve cerebral tissue NOS vigor, suppress the vigor of TChE, reduce serum and cerebral tissue MDA content.
Three, the D-galactose is caused the influence of mouse aging
Test objective: by observing yellow Pu Qing brain capsule the D-galactose is caused the influence of mouse aging, estimate its effect.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Huperzine A-Zhulin Antun (huperzine A sheet 0.05mg/ sheet), pharmaceutical factory in the He'nan Zhulin Zhongsheng Pharmaceutical Industry Co. Ltd Henan, lot number 050402.
Animal: Kunming mouse (secondary), body weight 25-28g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Reagent: superoxide dismutase (SOD) testing cassete, malonaldehyde (MDA survey) examination box are Nanjing and build up bio-engineering research institute product; The D-galactose, Shanghai reagent two factory's products.
The automatic test box of instrument DT-200 mice diving tower, Chengdu TME Technology Co., Ltd.; TDL-5-A type centrifuge, Anting Scientific Instrument Factory, Shanghai; FA2004 type electronic balance, balance equipment factory of last Nereid section; 722 type grating spectrophotometers, Shanghai the 3rd analytical tool factory.
Test method:
60 mices are divided into 6 groups at random, every group 10, be respectively normal control group, model control group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.78g/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug Huperzine A-Zhulin Antun group (0.1mg/kg is equivalent to 18 times of the clinical consumption of people).Administration group gastric infusion every day, capacity are the 0.2ml/10g body weight, and normal control group and model control group mice are waited the capacity distilled water every day, once a day, and the while nape Sc D-of portion galactose 120mg/kg, continuous 6 weeks
[3]The 2nd week, the 4th week, the 6th week carrying out step down test and test its learning capacity respectively at experiment, mice is placed on the safety board in the diving tower instrument adapts to 3min, turn-on current then, mice jumps off diving tower and is promptly shocked by electricity, be wrong reaction, its correct response is to jump onto the rubber platform after being shocked by electricity to hide electric shock.The record mice jumps off the time (incubation period) and the interior errors number of 5min of safety board for the 1st time.After test finishes, the mice broken end is got blood, separation of serum, 3000rpm, 4 ℃ of centrifugal 10min get serum by specification method and detect MDA, SOD content; Each treated animal broken end is fast got brain, separates brain cortical tissue on ice pan immediately, puts in-80 ℃ of refrigerators standby.Quantitatively take by weighing brain cortical tissue and make 1% homogenate, get supernatant by specification method and detect cerebral tissue MDA, SOD content, the histone assay is undertaken by the Lowry method.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
1. the D-galactose is caused the influence of mouse aging learning capacity
The results are shown in Table 11, table 12, from the result as seen, the model control group mice shortens (P＜0.01) at the 4th week, the 6th all two time point obviously normal matched groups incubation period of experiment, the 5min errors number illustrates that obviously more than normal control group (P＜0.01) mouse subcutaneous injection D-galactose 120mg/kg has caused learning memory disorder.Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice obviously prolongs (P＜0.05 or P＜0.01) than the model control group mice at the 4th week, the 6th all two time points of experiment incubation period, the 5min errors number obviously is less than model control group (P＜0.05 or P＜0.01), shows that decline has the improvement effect to learning and memory of little mouse for it.
Table 11 pair D-galactose cause the mouse aging learning capacity influence (diving tower method) (
, n=10)
| Group | Dosage (g/kg) | Wrong number (number of times) in 5 minutes | ||
| 2 weeks | 4 weeks | 6 weeks | ||
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 2.3±2.00 4.2±2.15 3.0±1.56 3.5±2.46 3.5±1.51 3.6±2.17 | 2.0±1.76 ** 5.9±2.28 3.3±2.31 * 3.8±1.14 * 2.9±1.79 ** 2.7±1.89 ** | 2.1±2.02 ** 6.5±2.32 3.8±1.62 ** 2.7±1.57 ** 3.3±1.77 ** 2.5±1.78 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
Table 12 pair D-galactose cause the mouse aging learning capacity influence (diving tower method) (
, n=10)
| Group | Dosage (g/kg) | Incubation period (s) | ||
| 2 weeks | 4 weeks | 6 weeks | ||
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 168.4±104.34 110.4±34.91 190.1±52.54 195.0±68.76 184.4±45.59 144.6±41.46 | 182.6±68.71 ** 40.8±25.11 110.0±60.07 ** 121.1±59.48 ** 116.3±42.32 ** 107.4±28.91 ** | 152.6±60.83 ** 49.3±31.26 113.1±51.31 ** 122.4±43.57 ** 111.9±24.46 ** 131.0±47.52 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
2. the D-galactose is caused the influence of mouse aging SOD in serum, MDA content
The results are shown in Table 13, from the result as seen, the obviously normal matched group of model control group mice MDA content raises (P＜0.01), and the normal matched group of serum activity of SOD obviously reduces (P＜0.01); Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice MDA content all is starkly lower than model control group (P＜0.05 or P＜0.01), and serum activity of SOD all is higher than model control group (P＜0.05).
Table 13 pair D-galactose cause mouse aging SOD in serum, MDA influence (
, n=10)
| Group | Dosage (g/kg) | Number of animals (only) | SOD (NU/ml) | MDA (nmol/ml) |
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 10 10 10 10 10 10 | 363.7±95.15 **181.7±70.92 255.6±81.37 *286.0±99.37 *260.8±62.68 *254.0±43.51 * | 4.61±1.40 ** 9.39±2.08 7.26±1.92 * 6.89±1.12 ** 6.14±1.47 ** 6.68±1.16 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01
3. the D-galactose is caused the influence of mouse aging cerebral tissue SOD, MDA content
The results are shown in Table 13, from the result as seen, model control group mouse brain tissue SOD vigor all obviously reduces (P＜0.01) than normal matched group; MDA content all obviously increases (P＜0.01) than normal matched group; Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mouse brain tissue SOD vigor all improves (P＜0.01) than model control group, and MDA content all reduces (P＜0.01) than model control group.
Table 14 pair D-galactose cause mouse aging cerebral tissue SOD, MDA influence (
, n=10)
| Group | Dosage (g/kg) | SOD (NU/ml) | MDA (nmol/ml) |
| The yellow Pu Qing brain capsule of blank group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 22.00±3.32 ** 12.74±3.44 19.43±4.22 ** 20.64±3.82 ** 19.53±3.74 ** 18.27±3.24 * | 3.64±0.84 ** 6.44±1.89 4.53±1.13 ** 4.37±0.94 ** 4.46±1.35 ** 4.69±0.51 ** |
Compare with model control group:
*P＜0.05,
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule has some improvement to the ability of learning and memory obstacle that the D-galactose causes mouse aging, can improve serum and cerebral tissue SOD vigor, reduce MDA content, correct the disorder of radical metabolism, certain antioxidation is arranged.
Four, to the protective effect of focal cerebral ischemia in rats
Test objective:, estimate its preventive and therapeutic effect by observing of the influence of yellow Pu Qing brain capsule to focal cerebral ischemia in rats.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Hydergine (Hydergine sheet), Tianjin Hua Jin pharmaceutical factory, Novartis Pharma AG's co-production, lot number 020632.
Animal: SD rat (secondary), body weight 180--200g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Reagent: ferric chloride, Beijing chemical reagents corporation, lot number 03227; Red tetrazolium, Beijing chemical reagents corporation.
Test method:
With 60 rats, be divided into 6 groups at random, every group 10, be respectively sham operated rats, model control group, yellow Pu Qing brain capsule small dose group (0.28g/kg, amount to crude drug 1.71g/kg, be equivalent to 3.5 times of the clinical consumption of people), dosage group (0.56g/kg in the yellow Pu Qing brain capsule, amount to crude drug 3.42g/kg, be equivalent to 7 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.12g/kg, amount to crude drug 6.83g/kg, be equivalent to 14 times of the clinical consumption of people) and positive drug hydergine group (1.2mg/kg is equivalent to 14 times of the clinical consumption of people).Administration group rat gastric infusion every day 1 time, capacity is the lml/100g body weight, sham operated rats, model control group rat such as give at the capacity distilled water, continuous 7 days.After the administration in the 6th day 2 hours, respectively with each group rat with chloral hydrate anesthesia (35mg/Kg, ip), the reference literature method
[4], the mid point between right eye and auris dextra is made the otch of a vertical 1.5cm, carefully separates temporalis, exposes zygomatic process and temporal bone, and the head end 1-2mm place in zygomatic process opens the aperture that a diameter is 2mm with dental burr, and exposes the initial position of medium-sized artery.With the meninges teasing, have the quantitative filter paper article of 50% liquor ferri trichloridi, 10 μ l to apply on this section middle cerebral artery suction with minute hand, take off filter paper after 30 minutes, reuse 0.9% normal saline cleans local, and skin suture is put back in the cage and raised.The sham operated rats rat is not except that applying the liquor ferri trichloridi filter paper bar, and all the other operating procedures are with the model matched group.Postoperative continued administration 1 day, and 8 hours after surgery, 24 hours respectively, carried out the nervous symptoms scoring behind the method improvement by Bederson etc.
[5]Standards of grading: 1. carry the Mus tail and observe forelimb flexing situation, protract, be designated as 0 fen as two forelimb symmetries; As the offside forelimb of performing the operation shoulder flexing, elbow flexing, shoulder inward turning occur or has concurrently, is designated as 1 fen.2. rat is placed on the plane, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and be designated as 0 fen effectively; As operation collateral resistance is descended, be designated as 1 fen.3. rat two forelimbs are put on the wire netting, observed muscular tension.As bilateral muscular tension equity and be designated as 0 fen effectively; As the offside muscle of anterior limb tension force decline of performing the operation, be designated as 1 fen.4. carry the Mus tail, animal has ceaselessly to operation offside revolver, is designated as 1 fen.According to above standards of grading, full marks are 4 minutes, and mark is high more, and the nervous symptoms of animal is serious more.Rat was put to death in time point scoring back in 24 hours, cutd open and got brain, removed olfactory bulb and low brain stem, was cut into five with all equidistantly crown, inserted respectively in the 2%TTC solution and dyeed.The non-ischemic region in dyeing back is a rose, and infarct is a white.The infarct cerebral tissue is carefully dug down, weigh.With the percentage ratio of blocking tissue's weight and full brain weight as the cerebral infarction scope.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
1. to the influence of focal rats with cerebral ischemia nervous symptoms
The results are shown in Table 15, from the result as seen, model control group rat nervous symptoms is serious, and 8 hours after surgery, 24 hours two time point nervous symptoms of yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) group rat all alleviate than the model control group rat, and (P＜0.01) is lowered in scoring.
The influence of table 15 pair rats with cerebral ischemia nervous symptoms
| Group | Dosage (g/kg) | Number of animals (only) | The nervous symptoms scoring | |
| 8 hours | 24 hours | |||
| The yellow Pu Qing brain capsule of sham operated rats model control group hydergine group | - - 0.28 0.56 1.12 1.2mg | 10 10 10 10 10 10 | 0.0±0.00 ** 3.6±0.70 2.2±0.92 ** 2.0±1.15 ** 1.9±0.57 ** 1.6±0.84 ** | 0.0±0.00 ** 3.2±0.63 2.1±0.99 ** 1.7±1.06 ** 1.4±0.84 ** 1.3±0.82 ** |
Compare with model control group:
*P＜0.05;
*P＜0.01
2. to the influence of focal rats with cerebral ischemia cerebral infarction scope
The results are shown in Table 16, from the result as seen, yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) group rat blocking tissue weight all reduces (P＜0.01) than the model control group rat with the percentage ratio of full brain weight.。
The yellow Pu Qing brain capsule of table 16 is to the influence of rat experiment cerebral infarction infarction size
| Group | Dosage (g/kg) | Number of animals (only) | Cerebral infarction scope (blocking tissue's weight/full brain weight) |
| Sham operated rats | - | 10 | 0.00±0.00 |
| The yellow Pu Qing brain capsule of model control group hydergine group | - 0.28 0.56 1.12 1.2mg | 10 10 10 10 10 | 4.76±0.64 3.09±0.70 ** 3.14±0.69 ** 2.75±0.44 ** 3.02±0.63 * |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) can obviously improve the nervous symptoms of focal cerebral ischemia rat, dwindles infarction size, alleviates brain tissue impairment due to the local cerebral ischemia.
Four, scopolamine is caused the influence of mouse memory acquired disturbance
Test objective: observe yellow Pu Qing brain capsule causes the mouse memory acquired disturbance to scopolamine influence.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Huperzine A-Zhulin Antun (huperzine A sheet 0.05mg/ sheet), pharmaceutical factory in the He'nan Zhulin Zhongsheng Pharmaceutical Industry Co. Ltd Henan, lot number 050402; Scopolamine hydrobromide injection (0.3mg), Shanghai Hefeng Pharmaceutical Co., Ltd., lot number 20050206.
Animal: Kunming mouse (secondary), body weight 25--28g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Instrument: the automatic test box of DT-200 mice diving tower, Chengdu TME Technology Co., Ltd..
Test method:
60 mices are divided into 6 groups at random, be respectively normal control group, model control group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.78g/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug Huperzine A-Zhulin Antun group (0.1mg/kg, be equivalent to 18 times of the clinical consumption of people), 10 every group.Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, normal control group, model control group such as give every day at the capacity distilled water, continuous 12 days.Except that the normal control group, all the other respectively organize the equal lumbar injection scopolamine of mice 5mg/kg, begin training after 30 minutes
[6]During training, mice is put into the diving tower device, adapt to 3 minutes earlier, then energising.When animal was subjected to shocking by electricity, normal reaction was the rebound platform to avoid electric shock, and the mice biped the copper grid for getting an electric shock, and is considered as wrong reaction.Trained 5 minutes and write down wrong reaction number of times in the mice 5 minutes.Test after 24 hours, write down wrong reaction number of times in 5 minutes, promptly remember wrong reaction number of times in 5 minutes phases.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
The results are shown in Table 17, from the result as seen, the model control group mice is increased (P＜0.01) in training period and the obviously normal matched group of 5 minutes memory phases wrong reaction time number average, illustrates and causes the learning and memory acquired disturbance.Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice obviously reduces (P＜0.01) than model control group in training period and 5 minutes memory phases wrong reaction time number average.
The yellow Pu Qing brain capsule of table 17 causes the influence of mouse memory acquired disturbance to scopolamine
| Group | Dosage (g/kg) | Number of animals (only) | Wrong number in 5 minutes | |
| Training period | Testing period | |||
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 10 10 10 10 10 10 | 2.3±1.16 ** 4.7±1.49 2.8±1.23 ** 2.7±1.34 ** 2.6±1.43 ** 2.5±1.27 ** | 2.1±0.87 ** 4.2±1.03 2.2±1.03 ** 2.4±0.84 ** 2.3±0.67 ** 2.1±1.37 ** |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule can obviously improve scopolamine and cause the mouse memory acquired disturbance.
Five, sodium nitrite is caused the influence that mouse memory is consolidated obstacle:
Test objective: observe yellow Pu Qing brain capsule sodium nitrite is caused the influence that mouse memory is consolidated obstacle.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, and lot number 040220, capsule 's content place the mortar porphyrize to add water and grind well, and the suspension of making variable concentrations is standby; Huperzine A-Zhulin Antun (huperzine A sheet 0.05mg/ sheet), pharmaceutical factory in the He'nan Zhulin Zhongsheng Pharmaceutical Industry Co. Ltd Henan, lot number 050402; Sodium nitrite (analytical pure), Tianjin Standard Science company limited, lot number 20050714.
Animal: Kunming mouse (secondary), body weight 25--28g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Instrument: the automatic test box of DT-200 mice diving tower, Chengdu TME Technology Co., Ltd..
Test method:
60 mices are divided into 6 groups at random, be respectively normal control group, model control group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.7gg/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug Huperzine A-Zhulin Antun group (0.1mg/kg, be equivalent to 18 times of the clinical consumption of people), 10 every group.Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, normal control group, model control group such as give every day at the capacity distilled water, continuous 12 days.The last administration begins training after 30 minutes.During training, mice is put into reflective box, adapt to 3 minutes earlier, then energising.When animal was subjected to shocking by electricity, normal reaction was the rebound diving tower to avoid electric shock, and the mice biped the copper grid for getting an electric shock, and is considered as wrong reaction.Trained 5 minutes, and write down wrong reaction number of times in 5 minutes.After training finished, except that the normal control group, all the other respectively organized the equal lumbar injection sodium nitrite of mice 120mg/kg, test after 24 hours
[6], write down wrong reaction number of times in 5 minutes.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
The results are shown in Table 18, from the result as seen, each organize mice 5 minutes training periods errors number do not have obvious difference, in the testing period, yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) can obviously reduce by 5 minutes wrong reaction number of times (P＜0.05 or P＜0.01).
The yellow Pu Qing brain capsule of table 18 causes the influence that mouse memory is consolidated obstacle to sodium nitrite
| Group | Dosage (g/kg) | Number of animals (only) | Wrong number in 5 minutes | |
| Training period | Testing period | |||
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 10 10 10 10 10 10 | 1.6±0.84 1.8±1.55 1.9±1.10 1.6±0.97 1.5±1.08 1.7±1.06 | 2.0±1.56 ** 4.8±1.58 2.5±0.97 ** 2.8±1.23 ** 2.9±1.66 * 3.0±1.56 * |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule can obviously improve sodium nitrite and cause the mouse memory acquired disturbance.
Six, to the influence of 40% ethanol induced mice memory represents obstacle
Test objective: observe of the influence of yellow Pu Qing brain capsule to 40% ethanol induced mice memory represents obstacle.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Huperzine A-Zhulin Antun (huperzine A sheet 0.05mg/ sheet), pharmaceutical factory in the He'nan Zhulin Zhongsheng Pharmaceutical Industry Co. Ltd Henan, lot number 050402; Dehydrated alcohol (analytical pure), big forever chemical reagent development centre, Tianjin, lot number 20040304.
Animal: Kunming mouse (secondary), body weight 25--28g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Instrument: the automatic test box of DT-200 mice diving tower, Chengdu TME Technology Co., Ltd..
Test method:
60 mices are divided into 6 groups at random, be respectively normal control group, model control group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.78g/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug Huperzine A-Zhulin Antun group (0.1mg/kg, be equivalent to 18 times of the clinical consumption of people), 10 every group.Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, normal control group, model control group such as give every day at the capacity distilled water, continuous 12 days.After the last administration, began training in 1 hour, during training mice put into the diving tower device, adapt to 3 minutes earlier, energising then, when mice is subjected to shocking by electricity, normal reaction be the rebound platform to hide electric shock, the mice biped the copper grid for getting an electric shock, and is considered as wrong reaction.Trained 5 minutes and write down errors number in 5 minutes.Test after 24 hours, in preceding 30 minutes model group of test and each administration group mouse stomach 40% ethanol 0.1ml/10g body weight
[6], capacity normal saline such as normal control group mouse stomach.After 30 minutes, test mouse wrong reaction times in 5 minutes.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
The results are shown in Table 19, from the result as seen, each organize mice 5 minutes training periods the wrong reaction number of times do not have obvious difference, the model control group mice is increased (P＜0.01) at the obviously normal matched group of 5 minutes testing periods wrong reaction number of times, illustrates that mouse stomach 40% ethanol has caused learning and memory to reproduce obstacle.Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) group mice wrong reaction in 5 minutes time number average obviously reduces (P＜0.05 or P＜0.01) than model control group.
Table 19 pair 40% ethanol causes the influence that mouse memory reproduces obstacle
| Group | Dosage (g/kg) | Number of animals (only) | Wrong number in 5 minutes | |
| Training period | Testing period | |||
| The yellow Pu Qing brain capsule of normal control group model matched group Huperzine A-Zhulin Antun group | - - 0.36 0.72 1.44 0.1mg | 10 10 10 10 10 10 | 1.7±1.25 1.6±1.26 2.0±1.33 2.1±1.60 1.9±1.37 1.7±1.42 | 1.6±1.50 ** 4.6±1.58 3.1±1.29 * 2.7±1.16 ** 2.8±1.75 * 2.9±1.29 * |
Annotate: compare with model control group:
*P＜0.05;
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule can obviously improve the mouse memory reproduction obstacle that 40% ethanol causes.
Seven, to the protective effect of acute brain anoxia mice:
Test objective: observe of the protective effect of yellow Pu Qing brain capsule to acute brain anoxia mice.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; Huperzine A-Zhulin Antun (huperzine A sheet 0.05mg/ sheet), pharmaceutical factory in the He'nan Zhulin Zhongsheng Pharmaceutical Industry Co. Ltd Henan, lot number 050402.
Animal: Kunming mouse (secondary), body weight 18--22g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Test method:
50 mices are divided into 5 groups at random, every group 10, be respectively blank group, yellow Pu Qing brain capsule low dose group (0.36g/kg, amount to crude drug 2.20g/kg, be equivalent to 4.5 times of the clinical consumption of people), dosage group (0.72g/kg in the yellow Pu Qing brain capsule, amount to crude drug 4.39g/kg, be equivalent to 9 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.44g/kg, amount to crude drug 8.78g/kg, be equivalent to 18 times of the clinical consumption of people) and positive drug Huperzine A-Zhulin Antun group (0.1mg/kg is equivalent to 18 times of the clinical consumption of people).Administration group gastric infusion every day, capacity are the 0.2m1/10g body weight, and the blank group waits the capacity normal saline every day, continuous once a day 12 days, and 40 minutes time broken ends after the last administration, record broken end duration of dehiscing.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
The results are shown in Table 20, the result shows that yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) all can prolong dehisce the time after mice breaks end (p＜0.01).
The dehisce influence of time of table 20 pair acute brain anoxia mice
| Group | Dosage (g/kg) | Number of animals (only) | (s) dehisces the time |
| The yellow Pu Qing brain capsule of blank group Huperzine A-Zhulin Antun group | - 0.36 0.72 1.44 0.1mg | 10 10 10 10 10 | 18.4±4.30 24.3±4.73 ** 26.8±2.48 ** 28.4±4.97 ** 22.3±2.71 * |
Annotate: compare with the blank group:
*P＜0.05;
*P＜0.01
Conclusion: this result of the test shows: yellow Pu Qing brain capsule has the certain protection effect to the chmice acute cerebral anoxia.
Eight, to the influence of blood stasis rat blood rheological characteristic
Test objective: observe of the influence of yellow Pu Qing brain capsule to blood stasis model rat blood rheological characteristic.
Test material:
Medicine: yellow Pu Qing brain capsule dry powder (6.1g crude drug/g dry powder), Tianshi Pharmacey Technology Development Co., Ltd., Hebei provides, lot number 041001; FUFANG DANSHEN PIAN, the new Double-Crane Pharmaceutical Co., Ltd in Shanxi company limited is produced, lot number 040321; Adrenalin hydrochloride injection (1mg/ml) is produced lot number 031110 by Tianjin gold credit aminoacid company limited.
Animal: SD rat (secondary), body weight 180--200g, male, provide by Hebei province's Experimental Animal Center, credit number is SCXK (Ji) 2003-1-003, animal feed is also provided by this center.
Instrument: full-automatic self-cleaning hemorheology instrument LBY-N6B, Pulisheng Instruments Co., Ltd., Beijing.
Test method:
With 60 rats, be divided into 6 groups at random, every group 10, be respectively blank group, model control group, yellow Pu Qing brain capsule small dose group (0.28g/kg, amount to crude drug 1.71g/kg, be equivalent to 3.5 times of the clinical consumption of people), dosage group (0.56g/kg in the yellow Pu Qing brain capsule, amount to crude drug 3.42g/kg, be equivalent to 7 times of the clinical consumption of people), yellow Pu cephalocathartic capsule in high dose group (1.12g/kg, amount to crude drug 6.83g/kg, be equivalent to 14 times of the clinical consumption of people) and positive drug FUFANG DANSHEN PIAN group (0.5g/kg is equivalent to 14 times of the clinical consumption of people).Administration group rat gastric infusion every day 1 time, capacity is the 1ml/100g body weight, blank group and model control group rat are waited the capacity distilled water, continuous 7 days.The blank matched group subcutaneous injection normal saline in the 8th day, other respectively organizes 2 adrenalin hydrochlorides of equal subcutaneous injection, gives for the first time 8 μ g/kg, gives 6 μ g/kg for the second time, and midfeather 4 hours is given behind the epinephrine 2 hours for the first time, and animal is put 5min in the frozen water
[7], dispose back 24 hours, with the anesthesia of 20% urethane, abdominal aortic blood, wherein 1.5ml blood injects rapidly in the anticoagulant heparin pipe, is used to measure hemorheology after shaking up and learns index; 1.2ml blood is measured blood plasma viscosity and packed cell volume value with the blood capillary method in addition.
Statistical procedures: data are used
Spss11.0for window statistical software is adopted in expression, statistical procedures.
Result of the test:
The results are shown in Table 21, from the result as seen, each organizes rat plasma viscosity and packed cell volume does not have obvious difference, model control group rat whole blood viscosity (high, medium and low cutting) all raises (P＜0.001) than the blank group, illustrates that the rat skin lower injection epinephrine stimulates the model of the hyperamization stasis of blood to form with frozen water.Yellow Pu Qing brain capsule (1.12g/kg) group rat whole blood viscosity (high, medium and low cutting) all reduces (P＜0.01) than the model control group rat, and yellow Pu Qing brain capsule (0.56g/kg) group rat whole blood viscosity (low cutting) all reduces (P＜0.05) than the model control group rat.
The yellow Pu Qing brain capsule of table 21 is to the hemorheological influence of Blood stasis rat
| Group | Animal (only) | Dosage (g/kg) | Whole blood viscosity is low cuts | Cut in the whole blood viscosity | The whole blood viscosity height is cut | The blood capillary plasma viscosity | Erythrocyte hematocrit (%) |
| The yellow Pu Qing brain capsule of blank group model matched group compound Salviae Miltiorrhizae group | 10 10 10 10 10 10 | -- -- 0.28 0.56 1.12 0.5 | 11.19±1.31 ** 14.49± 1.84 13.39±1.49 12.52±1.82 * 10.94±2.10 ** 11.01±1.29 ** | 6.22±0.59 ** 7.94±0.74 7.28±0.78 6.97±0.80 5.91±0.73 ** 6.01±0.50 ** | 4.80±0.45 ** 5.88±0.49 5.58±0.73 5.45 ±0.57 4.63±0.42 ** 4.71±0.32 ** | 1.02±0.05 1.17±0.09 1.17±0.05 1.22±0.07 1.20±0.07 1.13±0.06 | 51.4±2.80 51.4±3.72 50.9±3.60 53.4±3.31 53.2±2.30 53.8±2.97 |
Compare with model control group:
*P＜0.05,
*P＜0.01
Conclusion: this result of the test shows: it is unusual that yellow Pu Qing brain capsule can improve blood stasis rat serum rheology index, has certain function of promoting blood circulation to disperse blood clots.
Brief summary
Pharmacodynamic test of active extract result shows: yellow Pu Qing brain capsule (0.28g/kg, 0.56g/kg, 1.12g/kg) can obviously improve the permanent ligation of bilateral common carotid arteries and cause the vascular dementia rats learning capacity, improve SOD vigor in serum and the cerebral tissue, reduce MDA content, increase NE, DA content in the cerebral cortex; The rising of the blood stasis rat whole blood contrast viscosity that epinephrine is caused with frozen water has the reduction effect; Can obviously improve the nervous symptoms of focal cerebral ischemia rat, dwindle infarction size, alleviate brain tissue impairment due to the local cerebral ischemia.Yellow Pu Qing brain capsule (0.36g/kg, 0.72g/kg, 1.44g/kg) can obviously improve cerebral ischemia re-pouring and cause the mouse memory obstacle, improves SOD in serum and the cerebral tissue, total NOS vigor, reduces MDA content, suppresses the TChE vigor; Improve the learning capacity that the D-galactose causes mouse aging, improve SOD vigor in serum and the cerebral tissue, reduce MDA content; Can obviously improve scopolamine and cause the mouse memory acquired disturbance; Obviously improving sodium nitrite causes mouse memory and consolidates obstacle; Obviously improve the memory represents obstacle that ethanol causes; Dehisce the time after can prolonging the mice broken end, the chmice acute cerebral anoxia is had the certain protection effect.Result of study provides necessary pharmacology's foundation for clinical application.
Claims (8)
1, a kind of Chinese medicine composition for the treatment of vascular dementia is characterized in that being being made by the crude drug of following weight portion ratio:
Rhizoma Curcumae Longae 300-450 part Rhizoma Acori Graminei 250-350 part Radix Notoginseng 100-150 Fen Herba Siegesbeckiae 200-300 part
Radix Ginseng 150-220 part Radix Polygoni Multiflori Preparata 150-220 part Hirudo 100-150 part Rhizoma Coptidis 150-220 part
Radix Paeoniae Alba 200-300 part Poria 150-220 part Radix Polygalae 250-350 part
2, medicine according to claim 1, the weight portion ratio of its crude drug is:
250 parts of 312.5 portions of Radix Notoginseng of 375 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
187.5 parts of 125 portions of Rhizoma Coptidis of 187.5 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
312.5 parts of 187.5 parts of Radix Polygalaes of 250 parts of Poria of the Radix Paeoniae Alba
3, medicine according to claim 1, the weight portion ratio of its crude drug is:
300 parts of 250 portions of Radix Notoginseng of 300 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 125 Fen Herba Siegesbeckiaes
220 parts of 100 portions of Rhizoma Coptidis of 215 portions of Hirudos of 187.5 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
350 parts of 180 parts of Radix Polygalaes of 200 parts of Poria of the Radix Paeoniae Alba
4, medicine according to claim 1, the weight portion ratio of its crude drug is:
300 parts of 350 portions of Radix Notoginseng of 450 parts of Rhizoma Acori Graminei of Rhizoma Curcumae Longae, 100 Fen Herba Siegesbeckiaes
180 parts of 150 portions of Rhizoma Coptidis of 150 portions of Hirudos of 150 parts of Radix Polygoni Multiflori Preparatas of Radix Ginseng
250 parts of 155 parts of Radix Polygalaes of 300 parts of Poria of the Radix Paeoniae Alba
5,, it is characterized in that this medicine is capsule, tablet, pill or oral liquid according to the arbitrary described medicine of claim 1-4.
6, medicine according to claim 5 is characterized in that this medicine is a capsule.
7, the preparation method of the described medicine of claim 6 is characterized in that may further comprise the steps:
1), the side's of getting Chinese crude drug, choosing is clean respectively, coarse crushing becomes the 5-10mm granule, presses the recipe quantity weighing.
2), get Rhizoma Curcumae Longae, add 8-12 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, 2-3 hour for the first time, 1-2 hour for the second time, extracting solution filtered, and merged, and behind the decompression recycling ethanol, suitably was condensed into relative density and was about 1.0-1.2 (60 ℃ of heat are surveyed), and is standby.
3), get Radix Notoginseng, Herba Siegesbeckiae, Radix Polygoni Multiflori Preparata, Rhizoma Coptidis, add 8-10 and doubly measure 50-70% ethanol, heating and refluxing extraction 1-3 time, each 2-3 hour, extracting liquid filtering merged, decompression recycling ethanol is condensed into relative density and is about 1.0-1.2 (60 ℃ of heat are surveyed), and is standby.
4), get Rhizoma Acori Graminei, add 8-12 times of water gaging, soak after 30-60 minute, extracted volatile oil 4-8 hour, volatile oil device is in addition collected, aqueous extract filters, and is standby.
5), water intaking trematodiasis, the Radix Paeoniae Alba, Poria, Radix Polygalae, add 8-10 times of water gaging, decoct 2-3 time, each 1-2 hour, extracting liquid filtering merged, add the aqueous solution after Rhizoma Acori Graminei is carried oil, being condensed into relative density is 1.10-1.15 (60 ℃ of heat are surveyed) clear paste, merges with extracting solution such as Rhizoma Curcumae Longae, Radix Notoginseng, mixing, put into vacuum drying oven, at temperature 60-70 ℃, drying under reduced pressure under the vacuum 0.04-0.06Mpa condition, dried cream powder is broken into 100 order powder, and is standby.
6), get Radix Ginseng, be ground into 100 order powder, standby.
7), get 5) and 6) preparation powder, add appropriate amount of auxiliary materials, formulation method is made capsule routinely.
8, the preparation method of the described medicine of claim 5 is characterized in that:
With step 5), 6 in the claim 7) preparation fine powder, formulation method is made tablet, pill routinely;
Or
With 2), 3), 4), 5) in the extract of preparation, add 6) in the granule fine powder of gained, make oral liquid according to a conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100788439A CN101069734B (en) | 2006-05-10 | 2006-05-10 | Chinese medicine composition for vascular cretinism and preparing method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100788439A CN101069734B (en) | 2006-05-10 | 2006-05-10 | Chinese medicine composition for vascular cretinism and preparing method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101069734A true CN101069734A (en) | 2007-11-14 |
| CN101069734B CN101069734B (en) | 2010-08-11 |
Family
ID=38897253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100788439A Expired - Fee Related CN101069734B (en) | 2006-05-10 | 2006-05-10 | Chinese medicine composition for vascular cretinism and preparing method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101069734B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579934A (en) * | 2011-12-14 | 2012-07-18 | 南京中医药大学 | Traditional Chinese medical composition used for treatment of vascular dementia and preparation and application thereof |
| CN102861290A (en) * | 2012-09-10 | 2013-01-09 | 冯伟敏 | Chinese medicinal preparation having brain-invigorating and intelligent-benefiting functions |
| CN104645015A (en) * | 2015-01-27 | 2015-05-27 | 广西中医药大学第一附属医院 | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation |
| CN108403881A (en) * | 2018-04-23 | 2018-08-17 | 成都中医药大学 | A kind of pharmaceutical composition for treating senile dementia and preparation method thereof and purposes |
| CN111569008A (en) * | 2020-05-09 | 2020-08-25 | 昆明医科大学 | A pharmaceutical composition for treating neurodegenerative diseases |
| CN113855750A (en) * | 2021-10-08 | 2021-12-31 | 苏同生 | Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1175857C (en) * | 2002-04-29 | 2004-11-17 | 马合奎 | Medicine for preventing and curing cerebrovascular dementia |
-
2006
- 2006-05-10 CN CN2006100788439A patent/CN101069734B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579934A (en) * | 2011-12-14 | 2012-07-18 | 南京中医药大学 | Traditional Chinese medical composition used for treatment of vascular dementia and preparation and application thereof |
| CN102861290A (en) * | 2012-09-10 | 2013-01-09 | 冯伟敏 | Chinese medicinal preparation having brain-invigorating and intelligent-benefiting functions |
| CN102861290B (en) * | 2012-09-10 | 2014-04-09 | 冯伟敏 | Traditional Chinese medicinal preparation having brain-invigorating and intelligent-benefiting functions |
| CN104645015A (en) * | 2015-01-27 | 2015-05-27 | 广西中医药大学第一附属医院 | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation |
| CN108403881A (en) * | 2018-04-23 | 2018-08-17 | 成都中医药大学 | A kind of pharmaceutical composition for treating senile dementia and preparation method thereof and purposes |
| CN111569008A (en) * | 2020-05-09 | 2020-08-25 | 昆明医科大学 | A pharmaceutical composition for treating neurodegenerative diseases |
| CN113855750A (en) * | 2021-10-08 | 2021-12-31 | 苏同生 | Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101069734B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101496865B (en) | Chinese medicament preparation for treating depression and anxiety as well as preparation method thereof | |
| CN101069734B (en) | Chinese medicine composition for vascular cretinism and preparing method therefor | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN101444611A (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN103800670A (en) | Traditional Chinese medicinal preparation for treating kidney-yang deficiency and preparation method thereof | |
| CN102988703A (en) | Traditional Chinese medicine preparation for treating kidney-yang deficiency and preparation method thereof | |
| CN104208418A (en) | Rosa laevigata michx health oral solution for securing essence, reducing urination and tonifying kidneys and preparation method thereof | |
| CN102233009B (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN108514623A (en) | A kind of drug and preparation method thereof for treating deficiency of the liver and kidney menopausal syndrome | |
| CN103566087B (en) | Pharmaceutical composition for treating cognitive disorder and application thereof in preparation of medicine for treating Alzheimer disease | |
| CN101677989A (en) | A drug composition for treatment and prevention of ischemic stroke and its preparation methods | |
| CN104208303B (en) | A kind of Chinese medicine preparation for treating hyperlipemia and preparation method thereof | |
| CN103028071B (en) | Traditional Chinese medicine composition for treating diarrhea-dominant irritable bowel syndrome and preparation method of traditional Chinese medicine composition | |
| CN104888158A (en) | Folium apocyni veneti oral liquid for enhancing immunity and preparation method thereof | |
| CN104707023A (en) | Traditional Chinese medicinal composition for treating polycystic ovary syndrome, and preparation method thereof | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101249145B (en) | Nerves- soothing Chinese medicinal composition and its applications for preparing climacteric syndrome medicament | |
| CN104606636B (en) | A kind of Chinese medicine composition for treating depression and preparation method thereof | |
| CN104288670B (en) | One kind treatment or/and prevention Alzheimer disease drugs composition and its production and use | |
| CN107648565A (en) | A kind of pharmaceutical composition for treating depression and preparation method thereof | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN101244127B (en) | Medicament for treating vascular dementia | |
| CN103479868B (en) | Traditional Chinese medicine for treating apprehensive and cowardly arrhythmia and preparation method | |
| CN108186821A (en) | A kind of Chinese medicine composition for treating nervous headache and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Niu Liying Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Niu Liying Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Niu Liying Document name: Third notice of examination advice |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20180510 |